Patient Satisfaction in Relapsing-Remitting Multiple Sclerosis: Benefits of Home-Based Self-Administration of Subcutaneous Ofatumumab Compared to Other High-Efficacy Treatments - Takeaways - MDSpire

Patient Satisfaction in Relapsing-Remitting Multiple Sclerosis: Benefits of Home-Based Self-Administration of Subcutaneous Ofatumumab Compared to Other High-Efficacy Treatments

  • By

  • Francesco Pastore

  • Emanuela Domenicone

  • Patrizia DellOro

  • Charlotte Lefort

  • April 20, 2026

  • 0 min

Share

  • 1

    Self-administration of subcutaneous ofatumumab at home leads to better patient-reported outcomes compared to other high-efficacy therapies.

  • 2

    Fewer than 25% of patients were offered home self-administration of high-efficacy therapy, indicating a gap in shared decision-making.

  • 3

    Patient preferences are increasingly important in therapeutic decision-making for multiple sclerosis treatment.

  • 4

    The study evaluates patient satisfaction with high-efficacy therapies, focusing on quality of life and treatment burden.

  • 5

    Understanding patient experiences with treatment administration can inform more personalized and sustainable therapeutic strategies.

Original Source(s)

Patient Satisfaction in Relapsing-Remitting Multiple Sclerosis: Benefits of Home-Based Self-Administration of Subcutaneous Ofatumumab Compared to Other High-Efficacy Treatments

  • by Francesco Pastore, Emanuela Domenicone, Patrizia DellOro, Charlotte Lefort

  • April 20, 2026

Related Content

Partial sensory rhizotomy in therapy-refractory and recurrent trigeminal neuralgia – a single center experience

Case Study: Ofatumumab-Induced Remission in Refractory Panuveitis Accompanied by Multiple Sclerosis

Editorial: Diffusion-weighted imaging: advances and implementations in neurology